MeSH tree: D12.776.124.486.485.114.224.075.785
Early in the pandemic, clinicians noticed that certain immunocompromised patients were experiencing persistent SARS-CoV-2 infections, some lasting weeks to months at a time.
Jan 26, 2024
1
71
Mice with human immune cells are a new way of testing anti-cancer drugs targeting the immune system in pre-clinical studies. Using their new model, a Kobe University research team successfully tested a new therapeutic approach ...
Dec 14, 2023
0
50
Patients with lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), often undergo progressive kidney damage, with approximately 20% of these patients advancing to end-stage renal disease.
Dec 13, 2023
0
55
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities.
Dec 11, 2023
0
43
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a "surprisingly high" response ...
Dec 11, 2023
0
43
For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology.
Jun 14, 2023
0
32
Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, causing a substantial health ...
May 10, 2023
0
95
Imagine not being able to stay outdoors during winter. Or having to put on gloves to open the fridge. New knowledge and better treatment give hope to people who suffer from a rare cold disease.
Feb 7, 2023
0
32
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.
Jan 13, 2023
0
99
A new research paper titled "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" has been published in Oncotarget.
Dec 13, 2022
0
44
